Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2016 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2015 Net Income$1.54M$1.54M−94.3% vs Q2 2015 EPS Diluted$0.06$0.06−98.9% vs Q2 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,065,000N/M ended Jun 30, 2016 · filed Aug 10, 2016 · 41 d after period end